An open-label, randomized, two-period crossover study to compare the pharmacokinetic and safety profile of single dose of TAK-070 (50 mg) under fed and fasting condition in healthy volunteer - An open-label, randomized, study to compare the pharmacokinetic and safety profile of single dose of TAK-070 under fed and fasting condition

开始日期2015-08-15

申办/合作机构-

JPRN-UMIN000010218 / Completed临床1期IIT

A Randomized, Double-Blind, Placebo-Controlled, Sequential, Ascending Single and Multiple Dose, Safety, Tolerability, and Pharmacokinetic Study of TAK-070 in Healthy Elderly Subjects - A Randomized, Double-Blind, Placebo-Controlled, Sequential, Ascending Single and Multiple Dose, Safety, Tolerability, and Pharmacokinetic Study of TAK-070 in Healthy Elderly Subjects

开始日期2013-03-11

申办/合作机构-

100 项与 TAK-070 相关的临床结果

登录后查看更多信息

100 项与 TAK-070 相关的转化医学

登录后查看更多信息

100 项与 TAK-070 相关的专利（医药）

登录后查看更多信息

项与 TAK-070 相关的文献（医药）

2010-11-01·Brain Research4区 · 医学

Ameliorative effects of a non-competitive BACE1 inhibitor TAK-070 on Aβ peptide levels and impaired learning behavior in aged rats

4区 · 医学

Article

作者: Hiroaki Fukumoto ; Jun Terauchi ; Hideki Takahashi ; Ryouta Maeda ; Masaomi Miyamoto ; Kaneyoshi Kato

We examined the effects of TAK-070, a novel non-competitive β-secretase (BACE1) inhibitor, on the levels of Aβ peptides and behavioral deficits in rats. TAK-070 reduced soluble Aβ40 and Aβ42 levels of the cerebral cortex in a time- and dose-dependent manner in young rats. We found that the insoluble Aβ42 content increased significantly with aging from 22 months old without changing Aβ40 content. TAK-070 normalized the Aβ42 levels to those in young rats when they were fed chow containing TAK-070 starting at 19 months old for 6.5 months. Repeated administration of TAK-070 to aged rats for 2 weeks ameliorated the impaired spatial learning in the Morris water maze task and reduced the levels of soluble and insoluble Aβ peptides at doses of 0.3-1mg/kg, (p.o.). Interestingly, TAK-070 significantly recovered the reduced brain synaptophysin levels in aged rats to those in young rats. Our findings support the idea that partial inhibition of BACE1 by TAK-070 exerts symptomatic as well as disease-modifying effects for the treatment of Alzheimer's disease.

2010-08-18·The Journal of Neuroscience1区 · 医学

A Noncompetitive BACE1 Inhibitor TAK-070 Ameliorates Aβ Pathology and Behavioral Deficits in a Mouse Model of Alzheimer's Disease

1区 · 医学

Article

作者: Hirode, Mitsuhiro ; Iwatsubo, Takeshi ; Miyamoto, Masaomi ; Tarui, Naoki ; Maeda, Ryouta ; Sagayama, Masumi ; Sakura, Yasufumi ; Kato, Kaneyoshi ; Kawamoto, Makiko ; Fukumoto, Hiroaki ; Hirai, Kazuko ; Matsui, Junji ; Terauchi, Jun ; Takahashi, Hideki ; Kakihana, Mitsuru ; Tomita, Taisuke

We discovered a nonpeptidic compound, TAK-070, that inhibited BACE1, a rate-limiting protease for the generation of Aβ peptides that are considered causative for Alzheimer's disease (AD), in a noncompetitive manner. TAK-070 bound to full-length BACE1, but not to truncated BACE1 lacking the transmembrane domain. Short-term oral administration of TAK-070 decreased the brain levels of soluble Aβ, increased that of neurotrophic sAPPα by ∼20%, and normalized the behavioral impairments in cognitive tests in Tg2576 mice, an APP transgenic mouse model of AD. Six-month chronic treatment decreased cerebral Aβ deposition by ∼60%, preserving the pharmacological efficacy on soluble Aβ and sAPPα levels. These results support the feasibility of BACE1 inhibition with a noncompetitive inhibitor as disease-modifying as well as symptomatic therapy for AD.

100 项与 TAK-070 相关的药物交易

登录后查看更多信息